Arcutis Biotherapeutics/$ARQT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arcutis Biotherapeutics
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Ticker
$ARQT
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
342
ISIN
US03969K1088
Website
ARQT Metrics
BasicAdvanced
$1.6B
-
-$1.04
1.78
-
Price and volume
Market cap
$1.6B
Beta
1.78
52-week high
$17.75
52-week low
$7.86
Average daily volume
2M
Financial strength
Current ratio
3.552
Quick ratio
3.111
Long term debt to equity
77.078
Total debt to equity
77.668
Interest coverage (TTM)
-5.35%
Profitability
EBITDA (TTM)
-115.931
Gross margin (TTM)
88.39%
Net profit margin (TTM)
-60.95%
Operating margin (TTM)
-57.00%
Effective tax rate (TTM)
-0.47%
Revenue per employee (TTM)
$620,000
Management effectiveness
Return on assets (TTM)
-18.43%
Return on equity (TTM)
-70.58%
Valuation
Price to revenue (TTM)
8.01
Price to book
11.42
Price to tangible book (TTM)
12.91
Price to free cash flow (TTM)
-14.609
Free cash flow yield (TTM)
-6.84%
Free cash flow per share (TTM)
-93.57%
Growth
Revenue change (TTM)
100.03%
Earnings per share change (TTM)
-60.88%
3-year earnings per share growth (CAGR)
-39.39%
What the Analysts think about ARQT
Analyst ratings (Buy, Hold, Sell) for Arcutis Biotherapeutics stock.
Bulls say / Bears say
Arcutis Biotherapeutics reported a significant revenue increase of approximately 366% in Q4 2024 compared to Q4 2023, indicating strong market adoption of their products. (nasdaq.com)
The company announced positive Phase 3 trial results for ZORYVE® (roflumilast) Foam 0.3% in treating psoriasis, published in JAMA Dermatology, which could lead to expanded indications and increased sales. (globenewswire.com)
Arcutis has a robust pipeline with multiple clinical programs for inflammatory dermatological conditions, including atopic dermatitis and alopecia areata, positioning the company for future growth. (arcutis.com)
Despite revenue growth, Arcutis reported a net loss of $25.1 million in Q1 2025, indicating ongoing profitability challenges. (arcutis.com)
The company has a high short interest of 12.06% of outstanding shares, suggesting that a significant number of investors are betting against the stock. (stockanalysis.com)
Arcutis's cash and cash equivalents decreased from $228.6 million at the end of 2024 to $198.7 million by March 31, 2025, which may raise concerns about cash burn rates. (arcutis.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
ARQT Financial Performance
Revenues and expenses
ARQT Earnings Performance
Company profitability
ARQT News
AllArticlesVideos
Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
GlobeNewsWire·1 week ago
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 weeks ago
Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arcutis Biotherapeutics stock?
Arcutis Biotherapeutics (ARQT) has a market cap of $1.6B as of June 20, 2025.
What is the P/E ratio for Arcutis Biotherapeutics stock?
The price to earnings (P/E) ratio for Arcutis Biotherapeutics (ARQT) stock is 0 as of June 20, 2025.
Does Arcutis Biotherapeutics stock pay dividends?
No, Arcutis Biotherapeutics (ARQT) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Arcutis Biotherapeutics dividend payment date?
Arcutis Biotherapeutics (ARQT) stock does not pay dividends to its shareholders.
What is the beta indicator for Arcutis Biotherapeutics?
Arcutis Biotherapeutics (ARQT) has a beta rating of 1.78. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.